Clinical Trials Logo

Conjunctival Neoplasms clinical trials

View clinical trials related to Conjunctival Neoplasms.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03515954 Completed - Clinical trials for Conjunctival Neoplasms

AS-OCT Guided Treatment of Diffuse CSCC

Start date: March 2014
Phase:
Study type: Observational

A prospective study was performed on 8 eyes of 8 patients who underwent amniotic membrane graft after diffuse conjunctival squamous cell neoplasia excision followed by topical mitomycin C 0.04% eye drop between March 2014 and January 2018.

NCT ID: NCT00705640 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Advanced Melanoma

Mel48
Start date: May 2008
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.

NCT ID: NCT00471471 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Start date: October 2008
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with GM-CSF, CpG 7909, and incomplete Freund's adjuvant may make a stronger immune response and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and how well vaccine therapy works in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by surgery.

NCT ID: NCT00456495 Completed - Clinical trials for Conjunctival Neoplasms

Effect of Ranibizumab on Malignant Conjunctival Neoplasia

Start date: March 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and tolerability of subconjunctival injection of ranibizumab in the treatment of malignant conjunctival neoplasia using the incidence and severity of adverse events. Our secondary objective is to assess the efficacy of ranibizumab treatment on malignant conjunctival neoplasia by evaluating tumor destruction or reduction as documented by slit-lamp photography and ultrasonographic imaging and the regression of blood vessels.